Barr Announces Reorganization of Senior Management, Business...( Christine Mundkur Fred Wilkinson Mi...),Health

Christine Mundkur, Fred Wilkinson, Mike Bogda, Timothy Sawyer Promoted;

Bill McKee's Role Expanded

MONTVALE, N.J., March 28 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced the restructuring of its senior management team to better align the Company's global generic and proprietary businesses, optimize operations, and increase efficiencies across the global organization. Barr's Chairman and Chief Executive Officer, Bruce L. Downey, announced the following promotions: Christine Mundkur, Esq. has been named Chief Executive Officer of Barr Laboratories, Inc., the Company's generic pharmaceutical business; Fred Wilkinson has been named Chief Executive Officer of Duramed Pharmaceuticals, the Company's proprietary products business; Mike Bogda has been named President and Chief Operating Officer, Barr Laboratories, Inc., reporting to Mundkur; and, Timothy Sawyer has been named Executive Vice President, Global Generic Sales and Marketing, Barr Laboratories, Inc. reporting to Mundkur. In addition, Bill McKee, Executive Vice President and Chief Financial Officer, Barr Pharmaceuticals, will assume expanded responsibilities.

Mundkur and Wilkinson will report directly to Downey, who will retain the position of Chairman and CEO of Barr Pharmaceuticals, Inc., but will no longer have the day-to-day management responsibilities that he assumed in August 2007.

"An optimally structured senior management team is key to reaching the full potential of our combined organization," said Downey. "These promotions and expanded responsibilities recognize the distinct contribution of five of our key executives -- Christine, Fred, Mike, Bill and Tim -- and will enable me to devote more time to
'/>"/>